XML 73 R62.htm IDEA: XBRL DOCUMENT
v3.20.2

Significant agreements - Genetech Collaboration Agreement (Details) $ in Thousands |  | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | ---
Feb. 21, 2020 USD ($) item | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($)
Significant agreements. |  |  |  |  |  |  |
Collaboration revenues |  | $ 3,842 | $ 614 | $ 6,542 | $ 8,520 |  |
Deferred revenue |  | 33,275 |  | 33,275 |  | $ 5,657 | $ 14,635
Genetech |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Number of Potential development candidates | item | 4 |  |  |  |  |  |
Upfront cash payment | $ 30,000 |  |  |  |  |  |
Number of immuno oncology targets | item | 2 |  |  |  |  |  |
Expansion Fee | $ 10,000 |  |  |  |  |  |
Number of collaboration programs | item | 2 |  |  |  |  |  |
Transaction price | $ 31,000 |  |  |  |  |  |
Collaboration revenues |  | 1,209 | $ 0 | 3,066 |  |  |
Deferred revenue |  | 27,635 |  | $ 27,635 |  |  |
Period over which performance obligations will be performed |  |  |  | 2 years |  |  |
Material rights exercise period |  |  |  | 4 years |  |  |
Genetech | Royalty |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Number of years over which royalty is payable |  |  |  | 10 years |  |  |
Genetech | Maximum |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Additional number of immuno oncology targets | item | 2 |  |  |  |  |  |
Regulatory, and initial commercialization milestones, payments receivable | $ 200,000 |  |  |  |  |  |
Genetech | Development milestone | Maximum |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Sales milestone payments, receivable | 65,000 |  |  |  |  |  |
Genetech | Regulatory milestone | Maximum |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Sales milestone payments, receivable | 135,000 |  |  |  |  |  |
Genetech | Collaboration Program 1 Performance Obligation |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Transaction price | 3,775 |  |  |  |  |  |
Genetech | Collaboration Program 2 Performance Obligation |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Regulatory, and initial commercialization milestones, payments receivable | 8,000,000,000 |  |  |  |  |  |
Transaction price | $ 7,550 |  |  |  |  |  |
Genetech | Specified Targeting Arm Material Right Arm Program One |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Number of initial collaboration programs exercised | item | 1 |  |  |  |  |  |
Sales milestone payments, receivable | $ 1,000 |  |  |  |  |  |
Transaction price | 330 |  |  |  |  |  |
Genetech | Two material rights associated with the LSR Go Option for Collaboration Programs One And Two |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Transaction price | 11,650 |  |  |  |  |  |
Genetech | Material rights for associated and limited substitution rights |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Transaction price | $ 1,115 |  |  |  |  |  |
Genetech | Two material rights for Expansion Options |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Number of expansion option collaboration programs | item | 2 |  |  |  |  |  |
Transaction price | $ 6,580 |  |  |  |  |  |
Genetech | Collaboration Program One and Two Performance Obligation | Maximum |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Sales milestone payments, receivable | $ 200,000 |  |  |  |  |  |
Genetech | Material rights |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |
Deferred revenue |  | $ 19,700 |  | $ 19,700 |  |  |

X
- Definition Additional number of immuno oncology targets. + References No definition available. + Details
Name: | bcyc_AdditionalNumberOfImmunoOncologyTargets
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of Regulatory, and initial commercialization milestones payments receivable by the entity. + References No definition available. + Details
Name: | bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of Sales milestone payments, receivable by the entity. + References No definition available. + Details
Name: | bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of upfront cash payment received from collaborative arrangement. + References No definition available. + Details
Name: | bcyc_CollaborativeArrangementUpfrontCashPaymentReceived
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expansion fee to per additional collaboration program. + References No definition available. + Details
Name: | bcyc_ExpansionFeePerAdditionalCollaborationProgram
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The duration of material rights exercised or expired. + References No definition available. + Details
Name: | bcyc_MaterialRightsExerciseOrExpiryTerm
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of collaboration programs. + References No definition available. + Details
Name: | bcyc_NumberOfCollaborationPrograms
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of expansion option programs (Dev Go option). + References No definition available. + Details
Name: | bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of immuno oncology targets. + References No definition available. + Details
Name: | bcyc_NumberOfImmunoOncologyTargets
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents number of initial Genentech Collaboration Programs exercised. + References No definition available. + Details
Name: | bcyc_NumberOfInitialCollaborationPrograms
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Potential development candidates. + References No definition available. + Details
Name: | bcyc_NumberOfPotentialDevelopmentCandidates
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents number of years over which royalty is payable. + References No definition available. + Details
Name: | bcyc_NumberOfYearsOverWhichRoyaltyIsPayable
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents period over which performance obligations will be performed. + References No definition available. + Details
Name: | bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allocated determined transaction price under revenue recognition arrangement. + References No definition available. + Details
Name: | bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_GenetechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcyc_AchievementOfMilestoneAxis=bcyc_DevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcyc_AchievementOfMilestoneAxis=bcyc_RegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationOnePerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationTwoPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsForExpansionOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationPerformanceOneAndTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |